Background: Drug Resistant tuberculosis is one of the most common barriers in treatment of tuberculosis. Diabetic patients have been identified to have an increased risk of drug resistance. The present study was conducted to assess drug resistance pattern, particularly MD-tuberculosis detected by CBNAAT/TRUENAAT in diabetic patients with pulmonary tuberculosis and to associate them with different clinicodemographic variables including blood sugar profile. Materials & Methods: A total of 157 diabetic patients with tuberculosis (aged 17-75 years) were enrolled in the study. Clinicodemographic assessment was done. CBNAAT/Truenat assessment was done for rapid assessment of drug resistance. Subsequently drug susceptibility test was also done. Diagnostic efficacy of CBNAAT/True NAT was assessed in terms of sensitivity, specificity, PPV, NPV and accuracy. Results: Mean age of patients was 49.76±14.05 years; 72.6% were males males; 51% urban residents, 53.5% unemployed/ retired or housewives. Smoking and alcohol use history was revealed by 42.7% and 32.5% patients. Prevalence drug resistance (rifampicin resistance) as revealed by TrueNAT-RR was 14.6%. On drug susceptibility test (DST), Rifampicin, isoniazid and pyrazinamide resistance was seen in 22 (14%), 2 (1.3%) and 1 (0.6%) patients respectively. DR-TB in diabetic patients with tuberculosis did not show a significant association with age, sex, place of residence, occupation, smoking and alcohol use. A significant association of DR-TB was seen with dyspnea, chest pain, duration of tuberculosis, duration of diabetes and level of glycemic control (HbA1c, fasting and post-prandial blood sugar). Sensitivity and specificity of TrueNAT against DST was 100% and 99.3% respectively for rifamipicin resistance. Conclusion: The findings of the study showed that CBNAAT/TrueNAT were useful modalities for evaluation of drug-resistant tuberculosis which showed a high correlation with diabetic factors.